Recently, it was shown that elevated expression of IGF-IR and IGF-II in GBM were associated with poor patient survival and that paracrine IGF-IR/IGF-II signaling promoted the expansion of a chemoresistant glioma subpopulation (26). The gene discussed is IGF1R; the disease is central nervous system cancer.